The latest biotech news

News and Trends 8 Mar 2019

HIV Drug Shows Promise for Treating Ulcerative Colitis Patients

A small molecule drug, developed by the company Abivax for treating HIV, has also shown promise for patients with the inflammatory bowel disease ulcerative colitis, reducing the disease severity consistently for over six months. Abivax tested the drug on patients with moderate-to-severe cases of ulcerative colitis, an inflammatory bowel condition that causes rectal bleeding and […]

March 8, 2019 - 3 minutesmins - By Jonathan Smith

influenza virus antiviral drugs atriva therapeutics germany tuebingen 1

News and Trends 8 Mar 2019

Flu Resistant to Antivirals? This Biotech Has a Drug for That

We are visiting the medieval German city of Tübingen this week. It hosts the biotech Atriva Therapeutics, which is developing antiviral drugs for influenza that can circumvent drug resistance. Mission: To make antiviral drugs that, unlike conventional drugs, target the host cell instead of the virus. This can prevent the virus from building resistance to […]

March 8, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 6 Mar 2019

Second Patient Achieves HIV Remission After Bone Marrow Transplant to Treat Cancer

For the second time in history, an HIV-positive patient with blood cancer has achieved HIV remission following a customized bone marrow transplant to treat their cancer from an HIV-resistant donor. The HIV-positive patient received a bone marrow transplant to treat the blood cancer Hodgkin’s lymphoma, from which he also suffered. The researchers used this cancer […]

March 6, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 5 Mar 2019

Seventure Continues Microbiome Investment Success with Second Fund

After the success of the world’s first fund dedicated to companies in nutrition, digital health, and the microbiome, the French venture capital firm Seventure Partners has completed the first closing of a second microbiome fund, which is expected to total €200M. The fund is the successor to Seventure’s Health for Life Capital fund, which was […]

March 5, 2019 - 3 minutesmins - By Jonathan Smith

biogen nightstar therapeutics gene therapy ophthalmology

News and Trends 4 Mar 2019

Biogen Acquires UK Biotech Developing Gene Therapy for Blindness

The big US biotech Biogen has agreed to acquire Nightstar Therapeutics for €773M ($877M), including Nightstar’s candidate gene therapies for inherited blindness. Expected to be complete by mid-2019, Biogen’s acquisition of Nightstar bags it the UK company’s most advanced program. Currently in phase III, the therapy targets choroidemia, an incurable genetic condition which causes progressive […]

March 4, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 1 Mar 2019

Rapid Response mRNA Vaccine Facility Gets €30M Funding

An mRNA vaccine facility, run by the German biotech CureVac, has received a €30M development grant to rapidly manufacture vaccines for regions hit by outbreaks of rabies, yellow fever and emerging diseases. CureVac is a company that develops vaccines made of mRNA, a molecule that lets cells translate genes into proteins. The company’s drug candidates […]

March 1, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 1 Mar 2019

Update: Hansa Biopharma Applies for EMA Market Approval for Kidney Transplant Drug

Update (01/03/2019): Hansa Biopharma (previously named Hansa Medical) has filed an application for marketing authorization for imlifidase with the EMA also for use in patients undergoing kidney transplants. Update (18/10/2018): Imlifidase has just been given Fast Track Designation by the FDA for application in transplantation. The designation should accelerate the treatment through the FDA’s regulatory process, with […]

March 1, 2019 - 3 minutesmins - By Jonathan Smith

hookipa cancer vaccine hiv cytomegalovirus

News and Trends 28 Feb 2019

Austrian Biotech Raises €33.2M to Fund Cancer Vaccines

A Series D round of €33.2M ($37.4M) is to help the biotech Hookipa advance the clinical development of therapeutic vaccines for virus-based cancers, as well as a prophylactic vaccine for cytomegalovirus, which can infect patients undergoing organ transplants. Currently at the preclinical stage, Hookipa’s therapeutic vaccines are designed to tackle cancers that are caused […]

February 28, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 27 Feb 2019

UK Biotech Gets Huge Grant to Launch Off-the-Shelf CAR-T Cancer Therapy to Clinic

The UK biotech Cell Medica has received a €7.6M ($8.7M) grant from the Cancer Prevention and Research Institute of Texas to advance an off-the-shelf CAR-T cell therapy that can work not only in blood cancer but also in solid tumors. The funding will help the company to develop a special type of CAR-T cell therapy […]

February 27, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 26 Feb 2019

Immuno-oncology Biotech Raises €31M to Progress T-Cell Boosting Therapy

The Swiss biotech Anaveon closed a very respectable €31M (CHF35M) Series A fundraising round to help progress its T-cell boosting, cancer-fighting treatment to the clinic. The company’s candidate therapy mimics the action of a protein called interleukin 2, which is naturally found in the body. Interleukin 2 stimulates the immune system to produce more infection-fighting […]

February 26, 2019 - 2 minutesmins - By Helen Albert

CRISPR Cas9 antimicrobial peptide antibiotic resistance

News and Trends 26 Feb 2019

Swiss Scientists Find ‘Silver Bullet’ Against Bacterial Infections

Using the gene editing tool CRISPR-Cas9, researchers in Lausanne have uncovered antimicrobial molecules in the fruit fly that can selectively kill certain bacteria. This could lead to new therapeutics combatting antimicrobial resistance, and even preventing infections before they start. The research shows the antimicrobial molecules, or peptides, have the potential to treat infections of pathogens […]

February 26, 2019 - 3 minutesmins - By Jonathan Smith

gene therapy ada scid orchard therapeutics

News and Trends 25 Feb 2019

Orchard Achieves Good Survival with Cell Therapy for Rare Immune Deficiency

All 20 patients with a rare immunodeficiency disease survived for at least two years after receiving a cell therapy developed by Orchard Therapeutics. The patients had a genetic disease called adenosine deaminase–deficient severe combined immune deficiency (ADA-SCID) — also known as bubble boy syndrome. Caused by a mutation on a vital gene, the disease weakens […]

February 25, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

HIV Drug Shows Promise for Treating Ulcerative Colitis Patients

Flu Resistant to Antivirals? This Biotech Has a Drug for That

Second Patient Achieves HIV Remission After Bone Marrow Transplant to Treat Cancer

Seventure Continues Microbiome Investment Success with Second Fund

Biogen Acquires UK Biotech Developing Gene Therapy for Blindness

Rapid Response mRNA Vaccine Facility Gets €30M Funding

Update: Hansa Biopharma Applies for EMA Market Approval for Kidney Transplant Drug

Austrian Biotech Raises €33.2M to Fund Cancer Vaccines

UK Biotech Gets Huge Grant to Launch Off-the-Shelf CAR-T Cancer Therapy to Clinic

Immuno-oncology Biotech Raises €31M to Progress T-Cell Boosting Therapy

Swiss Scientists Find ‘Silver Bullet’ Against Bacterial Infections

Orchard Achieves Good Survival with Cell Therapy for Rare Immune Deficiency

Subscribe to our newsletter to get the latest biotech news!

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!